Humicef-O Tablet is a combination antibiotic formulation containing Cefixime 200 mg, Ofloxacin 200 mg, and Lactobacillus 60 million spores, designed for the treatment of a broad spectrum of bacterial infections. Cefixime, a third-generation cephalosporin, exhibits bactericidal activity by inhibiting bacterial cell wall synthesis, effective against gram-positive and gram-negative pathogens. Ofloxacin, a fluoroquinolone antibiotic, acts by inhibiting bacterial DNA gyrase and topoisomerase IV, thereby preventing DNA replication and transcription, enhancing the antimicrobial spectrum particularly against resistant strains. The inclusion of Lactobacillus spores aids in maintaining and restoring normal gut flora disrupted by antibiotic therapy, reducing the risk of antibiotic-associated diarrhea and other gastrointestinal disturbances. Humicef-O is indicated for respiratory tract infections, urinary tract infections, gastrointestinal infections, skin and soft tissue infections, and sexually transmitted infections caused by susceptible organisms. The combination therapy offers a synergistic effect, improving clinical outcomes in mixed or resistant infections. It is essential to use Humicef-O under medical supervision, considering potential contraindications such as hypersensitivity to cephalosporins or fluoroquinolones, and to monitor for adverse effects including gastrointestinal upset, hypersensitivity reactions, and potential tendonitis associated with fluoroquinolones. The dosage and duration should be tailored according to the severity of infection and patient-specific factors.